相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment
Adrian Zajac et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
mTORC2-mediated direct phosphorylation regulates YAP activity promoting, glioblastoma growth and invasive characteristics
Brent Holmes et al.
NEOPLASIA (2021)
Dual Regulation of Histone Methylation by mTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM
Mio Harachi et al.
MOLECULAR CANCER RESEARCH (2020)
Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment
Anaelle A. Dumas et al.
EMBO JOURNAL (2020)
Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review
Michael A. Vogelbaum et al.
NEURO-ONCOLOGY (2020)
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma
Wolfgang Wick et al.
NEURO-ONCOLOGY (2019)
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival
Georgios Batsios et al.
SCIENTIFIC REPORTS (2019)
Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment
Dennis Heinzen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma
Kenta Masui et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
Prakash Chinnaiyan et al.
NEURO-ONCOLOGY (2018)
mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma
B. Holmes et al.
ONCOGENE (2018)
mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT
Yuchao Gu et al.
MOLECULAR CELL (2017)
Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
Angelica Benavides-Serrato et al.
PLOS ONE (2017)
Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line
Haruo Miyata et al.
CANCER GENOMICS & PROTEOMICS (2017)
Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms
Inan Olmez et al.
CLINICAL CANCER RESEARCH (2017)
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Qiwen Fan et al.
CANCER CELL (2017)
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Vanessa S. Rodrik-Outmezguine et al.
NATURE (2016)
mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment
Kenta Masui et al.
BRAIN PATHOLOGY (2015)
Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness
Nicholas Artinian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Significance of filamin A in mTORC2 function in glioblastoma
Naphat Chantaravisoot et al.
MOLECULAR CANCER (2015)
Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells
Simona Daniele et al.
SCIENTIFIC REPORTS (2015)
Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival
H. Artee Luchman et al.
CLINICAL CANCER RESEARCH (2014)
Current development of the second generation of mTOR inhibitors as anticancer agents
Hong-Yu Zhou et al.
CHINESE JOURNAL OF CANCER (2012)
Growth hormone-releasing hormone: not only a neurohormone
Hippokratis Kiaris et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2011)
Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells
Jun Sunayama et al.
STEM CELLS (2010)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
Arkaitz Carracedo et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
SY Sun et al.
CANCER RESEARCH (2005)
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
E Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang et al.
INVESTIGATIONAL NEW DRUGS (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
DD Sarbassov et al.
SCIENCE (2005)
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
E Jacinto et al.
NATURE CELL BIOLOGY (2004)
分享论文
